{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:30:16Z","timestamp":1769171416501,"version":"3.49.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012680","name":"Universit\u00e4tsklinikum Hamburg-Eppendorf","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012680","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jtct.2024.10.003","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:36:59Z","timestamp":1729078619000},"page":"20.e1-20.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-3840","authenticated-orcid":false,"given":"Radwan","family":"Massoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-1413","authenticated-orcid":false,"given":"Evgeny","family":"Klyuchnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Zeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Langebrake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0114-1011","authenticated-orcid":false,"given":"Christian","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Rathje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nico","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietlinde","family":"Janson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wolschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5103-9966","authenticated-orcid":false,"given":"Nicolaus","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.10.003_bib0001","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjh.12756","article-title":"Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review","volume":"165","author":"Patnaik","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0002","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2024.10.003_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2020.10.007","article-title":"Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"27","author":"Gagelmann","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"10.1016\/j.jtct.2024.10.003_bib0004","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1182\/blood.2023023476","article-title":"Management of adult patients with CMML undergoing allo-HCT: recommendations from the EBMT PH&G Committee","volume":"143","author":"Onida","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.10.003_bib0005","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia","volume":"11","author":"Kerbauy","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0006","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0007","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0008","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0009","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0010","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3324\/haematol.2019.218677","article-title":"Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia","volume":"105","author":"Woo","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2024.10.003_bib0011","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-016-2887-4","article-title":"Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML","volume":"96","author":"Holtick","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0012","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"Rodriguez-Arboli","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0013","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2024.10.003_bib0014","first-page":"S1","article-title":"Long-term survival in patients suffering from AML with a complex aberrant karyotype after early allogeneic stem cell transplantation using the FLAMSA-RIC regimen: results from a prospective phase II trial","volume":"41","author":"Schmid","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41409-018-0288-0","article-title":"Comparison of FLAMSA-based reduced intensity conditioning with treosulfan\/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP\/EBMT analysis","volume":"54","author":"Sheth","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0016","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.beha.2011.05.002","article-title":"Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need","volume":"24","author":"Shimoni","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0018","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1038\/s41375-022-01689-9","article-title":"Response to \"The WHO classification of haematolymphoid tumours\" (Editorial)","volume":"36","author":"Swerdlow","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.10.003_bib0019","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOH.0000000000000112","article-title":"Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies","volume":"22","author":"Padron","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.10.003_bib0021","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1038\/leu.2017.170","article-title":"High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group","volume":"31","author":"Kasenda","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2024.10.003_bib0022","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/bmt.2017.23","article-title":"High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study","volume":"52","author":"Schorb","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0023","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/cncr.30695","article-title":"High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission","volume":"123","author":"DeFilipp","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2024.10.003_bib0024","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/sj.bmt.1705863","article-title":"Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up","volume":"40","author":"Bacigalupo","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0025","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0026","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0027","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ejh.12615","article-title":"FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission","volume":"96","author":"Holtick","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0028","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2024.10.003_bib0029","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705259","article-title":"Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)","volume":"37","author":"Kr\u00f6ger","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/blood-2002-11-3615","article-title":"Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation","volume":"103","author":"Casper","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.10.003_bib0031","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2009.23.3429","article-title":"Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan\/fludarabine conditioning","volume":"28","author":"Casper","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0032","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428190701671051","article-title":"Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"48","author":"Shimoni","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2024.10.003_bib0033","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2024.10.003_bib0034","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbmt.2010.05.007","article-title":"Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies","volume":"17","author":"Nemecek","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0035","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00277-022-04822-x","article-title":"Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis","volume":"101","author":"Braitsch","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0036","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.10.003_bib0037","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-013-1774-5","article-title":"Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia","volume":"92","author":"Schneidawind","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0038","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/ajh.24823","volume":"92","author":"Eder","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0039","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.clml.2018.02.016","article-title":"Thiotepa 10 mg\/kg treatment regimen is superior to thiotepa 5 mg\/kg in TBF conditioning in patients undergoing allogeneic stem-cell transplantation","volume":"18","author":"El-Cheikh","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2024.10.003_bib0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clml.2020.01.007","article-title":"Effect of the Thiotepa Dose in the TBF conditioning regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia in complete remission: a report from the EBMT acute leukemia working party","volume":"20","author":"El-Cheikh","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2024.10.003_bib0041","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41409-022-01841-0","article-title":"Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation","volume":"58","author":"Banet","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0042","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/bmt.2015.278","article-title":"Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT","volume":"51","author":"Cahu","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0043","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41409-021-01550-0","volume":"57","author":"Swoboda","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.10.003_bib0044","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2024.10.003_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0727-4","volume":"12","author":"Saraceni","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0046","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ajh.25004","volume":"93","author":"Decroocq","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0047","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.10.003_bib0048","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2010.32.5001","article-title":"Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?","volume":"29","author":"Horan","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2024.10.003_bib0049","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3026(15)00146-5","article-title":"Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis","volume":"2","author":"Nagler","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T04:43:36Z","timestamp":1740890616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2666636724006961"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.003","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}